Kiniksa stock rocketed 20% after first-quarter results on April 29. The biotech stock then broke out of a cup base with a buy point of 28.15 on May 5. IBD MarketSurge shows that shares traded tightly ...

Regeneron’s shares (currently trading at $552.99) have posted a disappointing 18.9% loss, well below the S&P 500’s 4.5% gain.

Regeneron Pharmaceuticals Inc. closed 55.21% below its 52-week high of $1,211.20, which the company reached on August 27th.

Firstly, he noted that the launch of Eylea HD has exceeded expectations to date, contributing to a positive outlook for the company’s performance. Furthermore, the Dupixent COPD phase 3 readout ...

In light of the significant drop in Regeneron’s stock price, a natural question emerges: is REGN now a viable buying opportunity?

Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Flynn’s outlook, therefore, reflects a belief in the strength of Regeneron’s product pipeline and market strategy.

On investments, Regeneron's focus has largely been on developing its internal pipeline of oncology and immunology therapies, but collaborations have increased in recent years.

In a challenging market environment, Regeneron Pharmaceuticals Inc. (NASDAQ: REGN) stock has reached its 52-week low, trading at $641.91.

Despite these challenges, Bernstein analysts anticipate that Regeneron's stock will likely be range-bound during the first half of 2025.

On investments, Regeneron's focus has largely been on developing its internal pipeline of oncology and immunology therapies, but collaborations have increased in recent years.

We recently compiled a list of the 11 Oversold Blue Chip Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN ...